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Abstract
The parasite Plasmodium vivax is the most frequent cause of malaria outside of sub-Saharan Africa, but efforts to develop
viable vaccines against P. vivax so far have been inadequate. We recently developed pathogen-mimicking polymeric vaccine
nanoparticles composed of the FDA-approved biodegradable polymer poly(lactide-co-glycolide) acid (PLGA) ‘‘enveloped’’
by a lipid membrane. In this study, we sought to determine whether this vaccine delivery platform could be applied to
enhance the immune response against P. vivax sporozoites. A candidate malaria antigen, VMP001, was conjugated to the
lipid membrane of the particles, and an immunostimulatory molecule, monophosphoryl lipid A (MPLA), was incorporated
into the lipid membranes, creating pathogen-mimicking nanoparticle vaccines (VMP001-NPs). Vaccination with VMP001-NPs
promoted germinal center formation and elicited durable antigen-specific antibodies with significantly higher titers and
more balanced Th1/Th2 responses in vivo, compared with vaccines composed of soluble protein mixed with MPLA.
Antibodies raised by NP vaccinations also exhibited enhanced avidity and affinity toward the domains within the
circumsporozoite protein implicated in protection and were able to agglutinate live P. vivax sporozoites. These results
demonstrate that these VMP001-NPs are promising vaccines candidates that may elicit protective immunity against P. vivax
sporozoites.
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Introduction
Plasmodium vivax is the most frequent cause of malaria outside of
sub-Saharan Africa and infects up to 390 million people each year
[1]. Despite its heavy burden on global health and potential for
spread outside of its endemic regions, P. vivax has not received as
much attention from the vaccinology community as P. falciparum,a
more virulent malaria strain [2]. However, recent studies have
suggested that the impact of P. vivax has been underestimated and
its public health burden is on the rise [3]. To address the lack of
potential vaccine candidates for P. vivax, we recently developed
vivax malaria protein (VMP001), a recombinant antigen derived
from the circumsporozoite protein (CSP), the most prevalent
membrane protein on sporozoites [4,5]. Our prior studies have
shown that VMP001 mixed with conventional adjuvants (e.g.,
Montanide) can elicit VMP001-specific antibody responses [4,5].
However, as shown in previous clinical trials, elicitation of
protective immunity against malaria sporozoites may require
more potent adjuvants that generate durable humoral immune
responses with increased avidity and affinity toward the CSP,
especially against potentially protective epitopes [6].
Robust antibody responses characterized by longevity and high
avidity require activation of B cells, followed by their affinity
maturation and differentiation into memory B cells and long-lived
plasma cells. To activate B cells, cell surface B-cell receptors (BCRs)
need to be crosslinked by binding to cognate epitopes in antigenin a
multivalent manner, as presented on the surfaces of foreign
pathogens [7,8]. Taking designcues from viral/bacterial pathogens,
many research groups have devised particulate vaccines that can
display repeat copies of antigens on the surfaces of particles, thus
enhancing activation of B cells and humoral immune responses
[9,10,11,12,13,14]. Inaddition,particlevaccinescanbeloadedwith
‘‘danger’’ signals that trigger Toll-like receptors (TLRs) or NOD-
like receptors (NLRs) in B cells and dendritic cells, thereby eliciting
robust humoral immune responses [9,15,16,17].
We recently reported the development of pathogen-mimicking
polymeric vaccine nanoparticles and microparticles, based on a
core of the FDA-approved biodegradable polymer poly(lactide-co-
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These particles were prepared by emulsifying an organic phase of
polymer and co-dissolved lipids in water, leading to self-assembled
lipid coatings surrounding each particle [18]. PLGA particles can
activate the inflammasome in antigen-presenting cells via NLRP3
and enhance innate and adaptive immune responses [20,21]. At
the particle surface, the lipid bilayers surrounding this PLGA core
can be incorporated with lipophilic pathogen-associated molecular
patterns (PAMPs) and protein antigens, creating particles with a
pathogen-mimetic composition of repeated antigen and PAMP
motifs [19]. Using this strategy, we co-delivered the Toll-like
receptor agonist monophosphoryl lipid A (MPLA) and/or the
natural killer T-cell ligand a-galactosyl ceramide together with the
model protein ovalbumin (OVA) bound to lipid-enveloped
particles with bacteria- or virus-like sizes (,2.5 mmo r,250 nm
diam., respectively), and showed that these pathogen-mimicking
particles can generate strong antigen-specific humoral and cellular
immune responses in vivo [19].
To determine whether this novel vaccine delivery platform using
FDA-approved materials could be used to enhance the immune
response against our candidate vivax antigen, here we synthesized
lipid-envelopedPLGA NPsdisplaying the VMP001malariaantigen
(VMP001-NPs), and tested their efficacy in generation of antigen-
specific humoral immune responses in vivo. Vaccination with
VMP001-NPs led to germinal center (GC) formation and elicited
durable antigen-specific antibodies with significantly higher titers
and more balanced Th1/Th2 responses, compared with soluble
protein vaccines.Antibodieselicited withNPvaccinesalsoexhibited
enhanced avidity and affinity toward the domains within CSP
implicated in protection and, ultimately, had the capacity to
agglutinate live P. vivax sporozoites, suggesting that these NP
vaccines may elicit protective immunity in field clinical trials.
Materials and Methods
Materials
PLGA with a 50:50 lactide:glycolide ratio was purchased from
Lakeshore Biomaterials (Birmingham, AL). The lipids 1,2-
dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-
glycero-3-phospho-(19-rac-glycerol) (DOPG), and 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-[maleimide] (mal-PE) were
purchased from Avanti Polar Lipids (Alabaster, AL). MPLA was
purchased from Sigma Aldrich (St. Louis, MO). n-succinimidyl s-
acetyl(thiotetraethylene glycol) (SAT(EG)4), 3,39,5,59 tetramethyl-
benzidine (TMB), strepavidin-coated ELISA plates, and 7000
MWCO desalting spin columns were from Pierce Biotechnology
(Rockford, IL). PEG-thiol (2 kMW) was purchased from Laysan
Bio (Arab, AL). The Lavapep Protein Quantification Assay was
obtained from Gel Company (San Francisco, CA). Horseradish
peroxidase (HRP)-labeled anti-mouse IgG, IgG1, IgG2b, IgG2c,
and IgG3 were purchased from Invitrogen (Carlsbad, CA). Anti-
B220, anti-IgD, anti-GL-7, and anti-goat IgG conjugated with
Alexa fluor 488 were obtained from BD Bioscience (Franklin
Lakes, NJ). Goat anti-his-tag IgG was obtained from Abcam
(Cambridge, UK) and peanut agglutinin was from Vectorlabs
(Burlingame, CA). Peptide epitope sequences were synthesized by
the Koch Institute Biopolymers Facility at MIT (Cambridge, MA).
All other reagents and solvents were obtained from Sigma Aldrich
and used as received unless noted otherwise.
Lipid-enveloped nanoparticle synthesis and
characterization
Lipid bilayer-enveloped nanoparticles were synthesized as
previously reported [18,19]. Briefly, a lipid solution containing
DOPC, DOPG, and mal-PE in a 4:1:5 molar ratio were do-
dissolved with 30 mg PLGA polymer (50:50 lactide:glycolide ratio)
in dichloromethane (DCM). In this organic phase, 200 ml PBS was
dispersed by sonication for 1 minute on ice using a Misonix
XL2000 Probe Tip Sonicator (Farmingdale, NY) at 7 W output
power. The resulting solution was immediately dispersed in 6 mL
distilled deionized (DDI) water by sonication for 3.5 min on ice
using the Misonix XL2000 at 12 W output power. DCM was
evaporated overnight at 25uC while agitating the solution on an
orbital shaker. To purify polymer-core nanoparticles from free
liposomes, particles were layered over a cushion of 30% sucrose in
ultrapure water and centrifuged at 13,0006g for 5 minutes. The
liposome-containing solution retained above the sucrose gradient
was discarded, and the particles pelleted below the sucrose
gradient were washed twice in PBS with centrifugation at 60006g
for 5 minutes. The PLGA particles were subsequently centrifuged
at 506g for 1 minute to remove large aggregates, and the
supernatant containing nanoparticles were used for conjugation
with VMP001 antigen. Particle sizes were determined by dynamic
light scattering (DLS) using a 90Plus/ZetaPals particle size
(Brookhaven Instruments) and confirmed with the Horiba Partica
LA-950V2 Laser Diffraction Particle Size Analysis System. SEM
images of particles were obtained by drying particles onto a
substrate, coating the dried particles with 15 nm of Au to using an
ion beam sputter coater (Gatan, Pleasanton, CA), and imaging the
samples using an FEI/Philips XL30 FEG ESEM with 15 kV
accelerating voltage.
VMP001 antigen
The design and production of VMP001 has been reported
previously [4,5]. Briefly, the Vivax Malaria Protein 001 represents
the circumsporozoite protein of P. vivax. It is comprised of a central
repeat region, encoding the repeat motifs of two major subtypes of
P. vivax, flanking the N- and C-terminal regions of the protein. The
antigen was cloned and expressed in E. coli and purified using
affinity and ion-exchange chromatography. It was tested to be free
of host contaminants, including endotoxin.
Conjugation of VMP001 to lipid-enveloped particles
To surface-display VMP001 on lipid-enveloped particles,
thiolated VMP001 was linked via maleimide-functionalized-PE
in the particle lipid coatings. First, VMP001 was modified with the
heterobifunctional cross-linker n-succinimidyl s-acetyl(thiote-
traethylene glycol) (SAT(EG)4) by adding a 10-fold molar excess
of the crosslinker (2.2 mM) to VMP001 solution (0.22 mM or
10 mg/mL) and incubating on a revolving rotator for 30 min at
25uC. To quench NHS groups on unreacted SAT(EG)4 molecules,
25 mM glycine was added, and the protein was incubated for an
additional 15 min rotating at 25uC. Quenched SAT(EG)4 was
removed by buffer exchange with a 7000 MWCO desalting spin
column. Sulfhydryl groups on SAT(EG)4-modified VMP001 were
deprotected by adding 50 mM hydroxylamine and 2.5 mM
EDTA (pH=7.4) and rotating for 2 hr at 25uC followed by a
second buffer exchange into 10 mM EDTA (pH=7.4). PLGA
particles were incubated with thiolated VMP001 (260 mg protein
per mg of PLGA NPs) for 2 hrs at 25uC before washing with sterile
saline to remove unbound antigen. PLGA particles conjugated
with VMP001 were then incubated with 2 kMW PEG-thiol at
10 mg/ml for 1 hr at 37uC before washing with sterile saline to
remove unbound PEG-thiol. The dose of protein on PEGylated
VMP001-NPs was determined by two methods. VMP001 was
stripped from particles using 0.2% Triton X-100 and the released
protein was quantified by direct fluorescence measurement (using
VMP001 labeled with Alexa Fluor 555), and also using the
PLGA Nanoparticles as a Malaria Vaccine
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on NPs was visualized with confocal microscopy (LSM510, Carl
Zeiss, Germany) after incubating VMP001-NPs with polyclonal
goat anti-his-tag antibody and Alexa-fluor 488 labeled anti-goat
IgG.
Immunizations
Mice were cared for in the USDA-inspected MIT Animal
Facility under federal, state, local and NIH guidelines for animal
care. All protocols for in vivo experiments were approved by the
Institutional Animal Care and Use Committee at the Massachu-
setts Institute of Technology (Approval number: 0708-074-11).
Groups of six- to ten-week old female C57Bl/6 mice (Jackson
Laboratories, Bar Harbor, ME) were immunized s.c. at the tail
base with 100 mL of VMP001 either in soluble or PLGA NP
formulations in PBS on days 0 and 21. The tail base site was
chosen based on pilot experiments comparing s.c. flank and tail
base immunizations, where tail base s.c. sites elicited ,10-fold
higher antibody responses in all groups (data not shown). Doses
chosen for these studies were motivated by our initial studies using
Freund’s adjuvant or Montanide [4,5], where we found 1–10 mgo f
VMP001 elicited substantial IgG titers in mice. Indicated doses of
TLR-4 agonist, MPLA, were admixed either to soluble VMP001
or VMP001-NP prior to both prime and boost immunizations.
Characterization of anti-VMP001 sera
At various time points, sera were collected and tested for anti-
VMP001 antibodies by ELISA [5]. Briefly, 96-well plates coated
with 0.04 mg of VMP001 in PBS at 25uC overnight were washed
with PBS-Tween20, and blocked with 0.5% casein in PBS for an
hour. The plates were incubated with sera diluted in 0.5% casein
buffer for 2 hr at 25uC, developed using horseradish peroxidase
(HRP)-labeled anti-mouse IgG, IgG1, IgG2b, IgG2c, or IgG3 and
3,39,5,59 tetramethylbenzidine (TMB), and read at A450. Anti-
VMP001 serum titers were defined as the lowest sera dilution at
which optical density (OD) reading was $0.5. Avidity measure-
ments were performed by adding an extra step of incubation with
6 M urea for 10 min at 25uC and washing prior to incubation with
anti-mouse IgG antibody to remove weakly bound IgG from plates
[22]. The avidity index was defined as:
Avidity index~ serum titer with 6 M urea=serum titer without ð
6 M urea treatmentÞ|100
For epitope analysis of sera, streptavidin-coated ELISA plates were
incubated with 50 mg/ml of the following epitopes from VMP001:
Type-1 repeat (GDRAAGQPAGDRADGQPA), AGDRx5 (AG-
DRAGDRAGDRAGDRAGDR), Region I (NPRENKLKQP),
Region II (EWTPCSVTCGVGVRVRRR), C-terminus (PNEK
SVKEYLDK), and a scrambled peptide control (KPLDVEKN-
SEY), each synthesized with biotin-GSSSG as spacer at the N-
terminus. After 12 hr incubation at 4uC, anti-VMP001 IgG titer
measurements were performed as described above for VMP001-
coated plates.
Cytokine analysis
C57Bl/6 mice were vaccinated on days 0 and 21 with 1 mg
VMP001 and alum or with 5 mg MPLA in either soluble or PLGA
formulations, and splenocytes isolated on day 28 were stimulated
with 25 mg/ml VMP001 ex vivo. After 2 days, cytokine levels in the
culture supernatants were measured by flow cytometry-based
multiplex cytokine analysis kit (Cytometric Bead Array, BD).
Germinal center analysis
On day 21 after immunization with 0.1 mg VMP001 either in
soluble or PLGA NP formulations and 5 mg MPLA s.c. at tail base,
draining inguinal lymph nodes were isolated, stained with markers
for GCs, anti-B220, anti-IgD, anti-GL-7, peanut agglutinin, and
analyzed with flow cytometry. To visualize GCs in draining
inguinal lymph nodes, cryosectioned lymph nodes were fixed in
4% paraformaldehyde, blocked with 1% BSA, stained with anti-
B220, anti-IgD, and anti-GL-7, and visualized with confocal
microscopy.
Live P. vivax sporozoite immunofluorescence assay
Anopheles dirus mosquitoes were fed with blood collected from
P. vivax-infected patients. Sporozoites were obtained from the
salivary glands of infected mosquitoes approximately 17 to 21
days after the blood meal and typed for the VK210 subtype of
P. vivax. Sporozoites were washed with PBS and then incubated
with equal volumes of mouse anti-VMP001 sera for 30 min.
Anti-mouse IgG-fluorescein isothiocyanate diluted 1:40 in
PBS–0.1% BSA was added to the slide, and after 30 min the
slides were observed by fluorescence microscopy at 406
magnification.
Statistical analysis
Statistical analyses were carried out using GraphPad Prism 5.0c
software. Student’s t test was used to compare two groups. Two-
way analysis of variance (ANOVA), followed by a Bonferroni post-
test was used to compare .2 groups. p-values less than 0.05 were
considered statistically significant. All values are reported as mean
6 s.e.m.
Results
Synthesis of lipid-enveloped PLGA NPs displaying malaria
antigen and adjuvant
Lipid-enveloped PLGA NPs were synthesized by a W:O:W
double-emulsion/solvent evaporation method, with PLGA and
lipids (DOPC:DOPG:maleimide-headgroup phosphoethanola-
mine in a 4:1:5 mol ratio) co-dissolved in the organic phase.
Self-assembly of lipid at the surface of each NP allowed subsequent
conjugation of thiolated VMP001 to maleimide groups displayed
in the lipid coating of the particle surfaces (Fig. 1A). In a typical
VMP001-NP synthesis, 2663.2 mg of VMP001 was conjugated
per mg of lipid-coated PLGA with 1062% protein conjugation
efficiency, as measured with fluorophore-tagged VMP001 and
independently by a commercial fluorescence-based protein
quantification assay. After antigen conjugation, the percentage of
remaining reactive maleimide groups on the particles decreased to
2667.6%; the remaining reactive groups were quenched by
coupling with 2 KDa thiol-terminated PEG. VMP001-NPs
examined under a scanning electron microscope showed a
relatively homogenous particle size distribution (Fig. 1B). Dy-
namic light scattering measurements indicated that PEGylated,
VMP001-displaying PLGA NPs (VMP001-NPs) had a mean
hydrodynamic diameter of 290 nm. To confirm that VMP001 was
conjugated on the membranes of particles, we probed for surface-
exposed VMP001 bound to the NPs using antibodies against the
C-terminal his-tag of the VMP001 protein. VMP001-NPs
incubated with anti-his-tag antibodies and fluorophore-conjugated
secondary antibodies showed antibody binding to the particles
(Fig. 1C) while control particles without VMP001 showed no
staining (not shown), indicating that the antigen was linked to the
membranes of VMP001-NPs.
PLGA Nanoparticles as a Malaria Vaccine
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responses at 10-fold lower doses of antigen than soluble
protein
We first investigated the effect of conjugating VMP001 to
particles by evaluating the humoral immune responses against the
antigen in the presence or absence of MPLA, a TLR-4 agonist.
C57Bl/6 mice were immunized on days 0 and 21 with 2.5 mgo f
VMP001-NP or soluble VMP001, with or without the addition of
25 mg MPLA. Serum VMP001-specific IgG titers were measured
over time by ELISA. Vaccination with VMP001-NP generated
higher titers than soluble VMP001. However, addition of MPLA
to both vaccine formulations resulted in significantly elevated
VMP001-specific IgG titers that were maintained for over 6
months (Fig. 2A). In particular, vaccinations with VMP001-
NP+MPLA elicited significantly higher antibody titers compared
with soluble VMP001+MPLA vaccines (days 35, 125 and 174 with
p,0.001, p,0.05, and p,0.05, Fig. 2A). Based on these results,
our subsequent immunization studies were all performed with
vaccines mixed with MPLA.
To further delineate the effect of delivering VMP001 on lipid-
shell PLGA NPs, mice were immunized with titrated doses of
VMP001 in NP or soluble formulations. Immunizations with
VMP001-NP mixed with 25 mg MPLA elicited high titers of serum
IgG against the antigen with as little as 100 ng of antigen, which
were maintained for more than 6 months (Fig. 2B). In contrast,
vaccines composed of soluble protein mixed with 25 mg MPLA
Figure 1. Synthesis of PLGA NPs with surface-conjugated
VMP001 (VMP001-NPs). (A) Schematic illustration of synthesis of
lipid-enveloped PLGA NPs with surface-conjugated VMP001. PLGA NPs
were incubated with thiolated VMP001, conjugating the antigen to
maleimide-functionalized lipids displayed on the particle membranes.
Particles were then PEGylated in a reaction with PEG-thiol. (B) A
scanning electron microcopy image of VMP001-NPs. Scale bar, 2 mm. (C)
Confocal microscopy image of VMP001-NPs incubated with anti-his-tag
and fluorescent secondary antibodies to detect particle surface-
conjugated VMP001. Scale bar, 10 mm.
doi:10.1371/journal.pone.0031472.g001
Figure 2. VMP001-NP vaccination mediates potent humoral immune responses. (A) C57Bl/6 mice were immunized s.c. on days 0 and 21
with 2.5 mg of VMP001 in either soluble or VMP001-NP formulations, with or without the addition of 25 mg MPLA. Anti-VMP001 IgG serum titer were
monitored over time by ELISA. (B) C57Bl/6 mice were immunized s.c. on days 0 and 21 with the indicated doses of VMP001 in either soluble or
VMP001-NP formulations with the fixed dose of 25 mg MPLA admixed in all groups. *, p,0.05, **, p,0.01, and ***, p,0.001, for VMP001-NP
formulations compared to soluble VMP001 vaccines at the same dose of antigen, analyzed by two-way ANOVA followed by Bonferroni post-tests.
doi:10.1371/journal.pone.0031472.g002
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titers achieved were maintained only transiently, with titers waning
rapidly after reaching a peak by day 56.
Sera from mice immunized and boosted with 1 mg of antigen
were obtained on days 35 and 120 post immunization and further
analyzed to determine the isotypes of antibodies generated by
soluble VMP001 vs. VMP001-NP immunization. At the specified
antigen dose, the nanoparticle vaccines promoted a more balanced
Th1/Th2 antibody response, with sustained IgG1 and IgG2c
responses and transient elicitation of IgG2b and IgG3 VMP001-
specific antibodies whereas soluble protein+MPLA generated
Th2-skewed, weak IgG1 antibody responses (Fig. 3A–E).
Although clear difference in the Th1/Th2 balance of the immune
response were detected in the antibody isotype analysis, measure-
ment of cytokine production by restimulated splenocytes ex vivo did
not reveal statistically significant differences in VMP001-NP,
soluble VMP001, or alum-immunized groups (Fig. 4).
Enhanced germinal center formation promoted by NP
vaccination
Long-lived, high titer humoral responses elicited by NP
immunizations suggest that the particle vaccine may promote
formation of germinal centers (GCs), which are specialized regions
in lymphoid organs where activated B cells proliferate and mature
to form long-lived memory B cells [23,24,25]. Prior studies of NP
vaccines have shown that the vast majority of particles accumulate
in draining lymph nodes and this is the site where GC reactions
occur [17]. Thus, to test the relative potency of soluble vs.
VMP001-NP vaccines to promote GC formation, we immunized
mice with a limiting dose of 5 mg MPLA and 0.1 mg soluble or
VMP001-NP and analyzed the response in draining lymph nodes
(dLNs). Flow cytometry analysis of dLNs on day 21 revealed that
VMP001-NP vaccines induced ,2.5-fold greater numbers of
isotype-switched GC B-cells (B220
+IgD
lowGL-7
+PNA
+), compared
to soluble VMP001+MPLA vaccines (p,0.05, Fig. 5A). In
addition, immunohistochemical analysis of dLNs on day 21
showed that even this very low dose of antigen when delivered by
NPs promoted recognizable GL-7
+ germinal center formation,
whereas organized GCs were absent in mice immunized with the
same doses of soluble protein mixed with MPLA (Fig. 5B).
VMP001-NP generates high affinity antibodies against
the repeat domains of the CS antigen
Although it is not yet clear which regions of the P. vivax CSP
confer antibody-mediated protection against sporozoites, several
studies thus far have suggested that a humoral response against the
Type I repeat is sufficient to induce protection [26], and
specifically, the AGDR motif within the VK210 sequence has
been identified as the target epitope of a monoclonal antibody that
confers protection [27,28]. We therefore assessed the quality of the
Figure 3. Immunization with VMP001-NPs elicits Th1/Th2 balanced antibody responses. (A) C57Bl/6 mice were immunized s.c. on days 0
and 21 with 25 mg of MPLA and 1 mg of VMP001 in either soluble or VMP001-NP formulations, and anti-VMP001 IgG sera were characterized on days
35 and 120 for (A) IgG, (B) IgG1, (C) IgG2b, (D) IgG2c, and (E) IgG3 titers.
doi:10.1371/journal.pone.0031472.g003
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specificity of sera against the recombinant CSP. The avidity index
of anti-VMP001 IgG was determined as the percentage of ELISA
antibody titers retained when sera bound to VMP001-coated
ELISA plates was exposed to urea, a chaotropic agent that disrupts
weakly bound antibodies [22]. VMP001-NP vaccines elicited IgG
responses with up to ,3-fold higher avidity against VMP001
compared to soluble protein vaccination, over the course of 6
months following prime and boost immunizations (p,0.001 for
day 90 and day 124, Fig. 6A).
Serum IgG from mice immunized with VMP001-NP bound the
Type I repeat domain with significantly higher titers than soluble
VMP001 vaccinations (Fig. 6B). In addition, VMP001-NP
vaccination elicited antibodies with robust binding to the AGDR
motif within the Type I repeat, whereas soluble VMP001 vaccines
failed to generate antibodies with the capacity to recognize this
protective domain (Fig. 6B). Interestingly, all the antibodies
generated with these soluble or NP immunizations were directed
toward only these two epitopes with minimal recognition of
peptides representing N- or C-terminal motifs of the protein. The
response to soluble protein vaccines might be altered by higher
antigen doses than 1 mg used in this current study, but these results
suggest that VMP001-NP+MPLA immunizations generate long-
lasting and high-avidity antibody responses with target specificity
against sporozoite domains thought to be critical in protective
immunity against infection.
NP immunization raises sera that can recognize and
agglutinate live sporozoites
Strong humoral immune responses, characterized by GC
formation and durable high-avidity antibody responses indicate
that VMP001-NP vaccines are promising candidates for a malaria
vaccine. To test whether antibodies generated with lipid-
enveloped PLGA vaccines can recognize native CSP antigens,
live VK210 P. vivax sporozoites were incubated with sera from
immunized mice, and IgG bound to the sporozoites was detected
by immunofluorescence. Sera from mice immunized with
VMP001-NP+MPLA and soluble VMP001+MPLA were both
able to bind to the live sporozoites (Fig. 6C, D), whereas sera
from unimmunized mice failed to bind to the parasites (not
Figure 4. Vaccination with VMP001-NPs enhances cellular immune responses. C57Bl/6 mice were vaccinated on days 0 and 21 with 1 mg
VMP001 and alum or with 5 mg MPLA in either soluble or VMP001-NP formulations, and splenocytes isolated on day 28 were stimulated with 25 mg/
ml VMP001 ex vivo. After 2 days, the supernatants were assayed for the presence of cytokines by ELISA.
doi:10.1371/journal.pone.0031472.g004
Figure 5. VMP001-NP immunization triggers germinal center formation. (A) C57Bl/6 mice were vaccinated with 0.1 mg VMP001 and 5 mg
MPLA in either soluble or VMP001-NP formulations, and on day 21, inguinal dLNs were isolated and analyzed for germinal center formation. The
number of isotype-switched germinal center B cells (GL-7
+PNA
+), gated on B220
+IgD
low populations in dLNs was measured with flow cytometric
analysis. (B) Inguinal dLNs were cryo-sectioned on day 21 post-immunization and stained with anti-B220, anti-IgD, and anti-GL-7 (markers for B cells,
immature B cells, and germinal center, respectively) and examined by confocal microscopy. Scale bars, 50 mm. *, p,0.05, analyzed by Student’s t test.
doi:10.1371/journal.pone.0031472.g005
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protein vaccines, live sporozoites incubated with sera from mice
immunized with VMP001-NP+MPLA showed extensive aggluti-
nation, suggesting that particle-immunized mice elicit antibodies
that could potentially render sporozoites inactive and non-
infectious [4].
Discussion
Particulate vaccine carriers can augment immune responses by
mimicking structural and compositional aspects of pathogens. Co-
delivery of antigens and adjuvant molecules using synthetic
particles in the size range of microbes is an efficient and potent
way to stimulate CD8
+ T cell and B cell responses, compared to
soluble antigen formulations [17,29,30,31]. We recently showed
that nano- or micro-particles prepared with a biodegradable
PLGA core and self-assembled surface lipid bilayer promoted
strong antibody responses against the model antigen ovalbumin
using tiny doses of antigen [19]. Here, we sought to enhance
humoral immune responses against a candidate malaria vaccine by
delivering the antigen conjugated to the surface membrane of
lipid-enveloped PLGA NPs. VMP001-NPs were designed with
pathogen-mimicking features, including their virus-like size range
(,300 nm diam.) and membrane composition with phospholipids
and immunostimulatory adjuvant, MPLA. To facilitate cross-
linking of BCRs and stimulation of B cell responses for strong
humoral responses, we conjugated multiple copies of the antigen
to each particle membrane, mimicking multivalent display of
antigen on viral and bacterial membranes.
Here we have shown that NPs bearing VMP001 and
adjuvanted with MPLA elicited significantly higher antibody titers
that were long-lasting at lower doses compared to vaccines
comprised of soluble protein mixed with MPLA. In addition,
compared to soluble formulations, NP vaccines generated a more
balanced Th1/Th2 humoral response with significantly enhanced
avidity, and required 10-fold less amount of antigen dose to
produce similar antibody titers up to 180 days. Notably, compared
to vaccination with soluble antigen, NP vaccinations generated
Figure 6. VMP001-NP immunization elicits high avidity antibodies capable of agglutinating live sporozoites. (A) Avidity indices of anti-
VMP001 IgG sera obtained from mice immunized as in Fig. 3 with soluble VMP001+MPLA (red circles) or VMP001-NP+MPLA (blue circles) were
characterized over 6 months following vaccination. *, p,0.01 and **, p,0.001, analyzed by two-way ANOVA, followed by a Bonferroni post-test. (B)
Anti-VMP001 IgG antibodies elicited with soluble VMP001+MPLA (red circles) or VMP001-NP+MPLA (blue circles) were further examined for their
affinities against key fragments of VMP001, including peptides representing the Type I repeat, AGDR motif, Region I, Region II, C-terminus, and
scrambled negative peptide control. Sera from non-immunized mice were also included as controls (black squares). (C,D) Sera obtain from mice on
day 63 post-immunizations with 2.5 mg VMP001 and 25 mg MPLA in either (C) soluble or (D) VMP001-NP formulations were incubated with live VK210
sporozoites, and immunoflurescence assay was performed to assess recognition of native CSP present on the surface of live sporozoites by anti-
VMP001 IgG sera. Mice immunized with VMP001-NP vaccines raised sera that agglutinated live VK210 subtype of P. vivax.
doi:10.1371/journal.pone.0031472.g006
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domain and AGDR motif, which are targets within VMP001
implicated in protective immunity against Plasmodium sporozoites
[4,26], suggesting that VMP001-NPs are potently activating B cells
with BCR specificity towards VMP001 domains critical for
protection against P. vivax sporozoites. It is possible that responses
to soluble antigen (Th1/Th2 balance, and avidity of humoral
responses) could alter as a function of antigen dose, and thus our
conclusions are limited by the range of doses explored here. Future
experiments will test whether the particle vaccines can elicit and
sustain improved humoral immune responses compared to soluble
protein vaccines using higher antigen doses and for longer
duration than examined in this current study.
The precise mechanism behind the enhanced affinity toward
these protective regions by particle vaccine is not known at this
point, but we can speculate that multivalent surface-display of
VMP001 on the lipid membrane of PLGA NPs may stimulate a
more diverse set of naı ¨ve B-cells, promoting stimulation of lower
avidity cells from the germline antibody repertoire, and enhance
affinity maturation during memory B cell development. As a
surrogate indicator for protection against malaria sporozoites, we
tested the functional efficacy of antibodies using a live sporozoite
agglutination assay, and found that the antibodies from mice
immunized with VMP001-NPs, compared to soluble protein
vaccines, were more efficient at recognition and agglutination of
sporozoites, highlighting the potential of NP vaccines to confer
protection against malaria infection. Maintenance of high avidity
and high titer antibodies against sporozoites may prevent invasion
of sporozoites into hepatocytes and initiation of malaria infection,
as it has been demonstrated that anti-sporozoite antibodies in
dermal tissues can inhibit migration of sporozoites from skin into
the systemic circulation via blood vessels [32].
There are two distinct antibody responses after exposure to
antigen. Short-lived plasmacellsdevelop inextrafollicularregions in
lymph nodes and transiently produce low-affinity antibodies. In
contrast, a subset of activated B cells proliferate within follicles to
form GCs, where antigen-experienced B cells undergo somatic
hypermutation and affinity maturation [33]. These high-affinity B
cells then differentiate into long-lived memory B cells or plasma
cells, establishing durable memory responses that quickly generate
strong humoral immune responses upon re-exposure to antigen
[23,25]. When examined in our model, NP vaccines,butnot soluble
protein vaccines, induced GC formation even withvery low doses of
antigen, partially explaining the high-affinity, long-lasting antigen-
specific antibody responses elicited with the particle vaccine.
Recent studies have shown that combinations of molecular
danger signals can synergize to further boost immune responses
when delivered by particulate vaccines [9,15,16,17,30,31]. For
delivery of multiple immunostimulatory molecules, lipid-‘‘envel-
oped’’ PLGA particles allow incorporation of both hydrophilic and
hydrophobic molecules in their internal trapped aqueous and
polymeric organic phases, respectively. In this current study, an
immunostimulatory molecule, MPLA, was added post-synthesis to
allow the lipophilic TLR4 agonist to decorate the surfaces of
particles [18]. However, lipid ‘‘enveloped’’ PLGA particles offer
additional avenues to incorporate adjuvant molecules for their
controlled release. Lipophilic adjuvant molecules, such as MPLA,
Pam3CysK (TLR-2 agonist), and lipid-conjugated CpG (TLR-9
agonist) recently developed in our laboratory [34], loaded in the
organic emulsion phase during synthesis will be partitioned
between the lipid layer and polymeric core, allowing their release
for an extended period [18]. In addition, hydrophilic adjuvant
molecules, such as unmethylated CpG, polyI:C (TLR-3 agonist),
and R848 (TLR-7/8 agonist), can also be entrapped in the PLGA
core during synthesis [35] or anchored to the membrane via a
lipophilic tail [34]. Future studies will be directed to examine the
effect of combination of dual or triple adjuvant molecules and their
controlled release on the characteristics of humoral immune
responses.
In summary, PLGA NPs displaying VMP001 and MPLA on
their surfaces potently elicited humoral immune responses against
the VMP001 CSP antigen, generating long-lasting antibody
responses in mice, characterized by enhanced avidity and capacity
to neutralize live sporozoites. NP vaccines thus may confer subunit
vaccines with enhanced efficacy against malaria sporozoites.
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